Currently, there are 677.29M common shares owned by the public and among those 672.79M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -3.97% and -5.52% over the past three months. CRH shares are trading 4.10% year to date (YTD), with the 12-month market performance up to 14.23% higher. It has a 12-month low price of $71.18 and touched a high of $110.97 over the same period. CRH has an average intraday trading volume of 4.07 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.28%, -2.15%, and 6.73% respectively.
Institutional ownership of CRH Plc (NYSE: CRH) shares accounts for 80.73% of the company’s 677.29M shares outstanding.
It has a market capitalization of $65.15B and a beta (3y monthly) value of 1.27. The stock’s trailing 12-month PE ratio is 19.12, while the earnings-per-share (ttm) stands at $5.04. The company has a PEG of 2.20 and a Quick Ratio of 0.91 with the debt-to-equity ratio at 0.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.21% over the week and 3.03% over the month.
Earnings per share for the fiscal year are expected to increase by 6.69%, and 10.84% over the next financial year. EPS should shrink at an annualized rate of 8.70% over the next five years, compared to 18.51% over the past 5-year period.
Looking at the support for the CRH, a number of firms have released research notes about the stock. HSBC Securities stated their Buy rating for the stock in a research note on November 11, 2024, with the firm’s price target at $116. Barclays coverage for the CRH Plc (CRH) stock in a research note released on October 29, 2024 offered a Overweight rating with a price target of $110. Morgan Stanley was of a view on July 09, 2024 that the stock is Overweight, while Stephens gave the stock Overweight rating on June 18, 2024, issuing a price target of $95. RBC Capital Mkts on their part issued Outperform rating on May 14, 2024.
